Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of
Open access · hybridAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 2 pooled it
75.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 2 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- Efficacy and safety of FLT3 inhibitors for acute myeloid leukemia: a network meta-analysis.Frontiers in oncology · 2026Pooled it
- Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML.Blood advances · 2026Trial
- Gilteritinib and chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.Blood advances · 2026Trial
- Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.Blood advances · 2026Trial
- CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.Nature medicine · 2026Trial
- FLT3-ITD measurable residual disease from the QuANTUM-First trial.Blood advances · 2026Trial
- Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.Blood advances · 2025Trial
- Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.Clinical epigenetics · 2025Trial
- Trial
- Trial
- Trial
- Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.Blood advances · 2024Trial
- Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.British journal of haematology · 2026Article
- Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.International journal of hematology · 2026Review
- Article
- The Pitfalls of Categorizing Donor Age: Arbitrary Cutoffs Fail to Predict Survival in Haploidentical HCT.American journal of hematology · 2026Article
- Article
- Recent advances in cell therapy for AML/MDS.International journal of hematology · 2026Review
- FLT3-Mutated AML: Transplanting with Precision in the Targeted Era.Current hematologic malignancy reports · 2026Review
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 20 institutions in 7 countries.
Mark J LevisJohns Hopkins University, Baltimore, MD.ORCID 0000-0003-0473-6982
Mehdi HamadaniCIBMTR/Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0001-5372-510X
Brent LoganCIBMTR/Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0002-4473-4044
Richard J JonesJohns Hopkins University, Baltimore, MD.
Anurag K SinghUniversity of Kansas, Kansas City, KS.
Mark LitzowMayo Clinic, Rochester, MN.ORCID 0000-0002-9816-6302
John R WingardUniversity of Florida, Gainesville, FL.ORCID 0000-0001-7478-5398
Esperanza B PapadopoulosMemorial Sloan Kettering Cancer Center, New York, NY.
Alexander E PerlUniversity of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-1463-2231
Robert J SoifferDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-5810-1192
Celalettin UstunRush University Medical Center, Chicago, IL.ORCID 0000-0001-6896-6213
Masumi Ueda OshimaFred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0003-2277-1976
Geoffrey L UyWashington University, St Louis, MO.ORCID 0000-0002-7809-0996
Edmund K WallerEmory University, Atlanta, GA.ORCID 0000-0003-0816-6729
Sumithra VasuOhio State University, Columbus, OH.
Melhem SolhNorthside Hospital Cancer Institute, Atlanta, GA.ORCID 0000-0003-3766-5623
Asmita MishraMoffitt Cancer Center, Tampa, FL.ORCID 0000-0003-3065-4294
Lori MufflyStanford University, Palo Alto, CA.ORCID 0000-0002-9887-6136
Hee-Je KimCatholic Hematology Hospital, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID 0000-0003-4098-3366
Jan-Henrik MikeschUniversity of Muenster, Münster, Germany.
Yuho NajimaTokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.ORCID 0000-0001-8910-0021
Masahiro OnozawaHokkaido University Hospital, Sapporo, Japan.ORCID 0000-0001-9267-2864
Kirsty ThomsonUniversity College Hospital, London, United Kingdom.
Arnon NaglerChaim Sheba Medical Center, Tel Hashomer, Israel.ORCID 0000-0002-0763-1265
Andrew H WeiPeter MacCallum Cancer Centre, Royal Melbourne Hospital, Walter and Eliza Hill Institute of Medical Research and University of Melbourne, Melbourne, Australia.ORCID 0000-0002-7514-3298
Guido MarcucciBeckman Research Institute of City of Hope, Duarte, CA.
Nancy L GellerNational Heart, Lung and Blood Institute, Bethesda, MD.ORCID 0000-0003-0500-7386
Nahla HasabouAstellas Pharma Inc, Northbrook, IL.
David DelgadoAstellas Pharma Inc, Northbrook, IL.
Matt RosalesAstellas Pharma Inc, Northbrook, IL.
Jason HillAstellas Pharma Inc, Northbrook, IL.ORCID 0000-0003-2512-1661
Stanley C GillAstellas Pharma Inc, Northbrook, IL.ORCID 0009-0001-0063-8755
Rishita NuthethiAstellas Pharma Inc, Northbrook, IL.
Denise KingThe Emmes Company, Rockville, MD.ORCID 0009-0007-3579-4196
Heather WittsackThe Emmes Company, Rockville, MD.
Adam MendizabalThe Emmes Company, Rockville, MD.
Steven M DevineNational Marrow Donor Program, Minneapolis, MN.ORCID 0000-0001-7731-759X
Mary M HorowitzCIBMTR/Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0002-9502-785X
Yi-Bin ChenMassachusetts General Hospital, Boston, MA.ORCID 0000-0002-9554-1058
BMT-CTN 1506/MORPHO Study Investigators
Astellas Pharma (United States) · USEmory University · USJohns Hopkins University · USNational Marrow Donor Program · USUniversity of Florida · USUniversity of Münster · DEDana-Farber Cancer Institute · USEmmes (United States) · USHokkaido University Hospital · JPMassachusetts General Hospital · USMayo Clinic in Arizona · USMedical College of Wisconsin · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USNorthside Hospital · USPalo Alto University · USRush University Medical Center · USThe Catholic University of Korea Seoul St. Mary's Hospital · KRThe Ohio State University · USUniversity College Hospital · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI WANCAI YANG · 1985 to 2026
$132.3MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MBlood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4MEasy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8MBMT CTN Core - Fred Hutchinson Cancer CenterUG1HL069246 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 2017 to 2026
$2.2MBMT CTN Core - Dana-Farber Cancer Institute and MGH ConsortiumUG1HL069249 · NHLBI · DANA-FARBER CANCER INST · PI Mahasweta Gooptu · 2017 to 2026
$2.2MTargeting HIV and EBV Antigens in Patients with HIV LymphomaUG1HL108945 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Catherine M. Bollard, HELEN E HESLOP · 2017 to 2026
$2.1MCore Clinical Centers for the Blood and Marrow Transplant Clinical Trials Network (UG1)UG1HL108987 · NHLBI · H. LEE MOFFITT CANCER CTR & RES INST · PI Joseph A Pidala · 2017 to 2026
$2.1MMount Sinai Core Clinical Consortium for the BMT Clinical Trials NetworkUG1HL138645 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JOHN LEVINE · 2017 to 2026
$1.9MPhase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell TherapiesUG1HL109137 · NHLBI · WASHINGTON UNIVERSITY · PI Iskra Pusic · 2017 to 2026
$1.9MBMT Core - Stanford UniversityUG1HL069291 · NHLBI · STANFORD UNIVERSITY · PI Lori Muffly · 2017 to 2026
$1.7MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016058NCI NIH HHS R50 CA275927NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U10 HL069301NHLBI NIH HHS U24 HL138660NHLBI NIH HHS UG1 HL069246NHLBI NIH HHS UG1 HL069249NHLBI NIH HHS UG1 HL069291NHLBI NIH HHS UG1 HL069310NHLBI NIH HHS UG1 HL108945NHLBI NIH HHS UG1 HL108987NHLBI NIH HHS UG1 HL109137NHLBI NIH HHS UG1 HL138645
Abstract
purposeAllogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of
methodsAdults with
resultsThree hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided
conclusionAlthough the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable
Indexed as
Aniline Compoundsfms-Like Tyrosine Kinase 3Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMutationPyrazinesAdultAgedFemaleGene DuplicationHumansMaintenance ChemotherapyMaleMiddle AgedNeoplasm, ResidualProtein Kinase InhibitorsAniline Compoundsfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsPyrazines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.